

INVITATION

TO AN INTERACTIVE DINNER PROGRAM

WE WANT YOUR FEEDBACK!



The program will discuss a NEW biomarker in HR+ breast cancer DiviTum™TKa, an FDA cleared novel cell proliferation blood test that measures circulating thymidine kinase activity (TKa). The test is indicated for monitoring disease progression in breast cancer patients.


We will be reviewing the most recent TKa research data from the SABCS meeting presented by one of the lead authors:

- **TKa in the adjuvant setting**
- **Using TKa levels to select patients for continued CDK4/6i based therapy after progression on a CDK4/6i**
- **Correlations and differences between TKa and ctDNA in patients with HR+ MBC**

FDA-cleared!

Monitoring
MBC Treatment
with Simply
a Blood Test

For postmenopausal
women with
HR+ breast cancer



MAVERICK
TEXAS BRASSERIE

This will take place at:

Maverick Texas Brasserie
710 S. St. Mary's St
San Antonio, TX

Wednesday, December 11th @ 7:15 pm

Space is
limited

Book here!

The venue is a 15 minute walk from the convention center.